The FDA has approved pembrolizumab immunotherapy, the first treatment to lower kidney cancer recurrence risk after surgery. UT Southwestern's Dr. Hans Hammers helps patients explore its benefits and risks.
Cancer death rates have dropped nearly 30% since 1991, and more that 2% between 2016 and 2017 alone – the biggest one-year drop on record. The driver has been precision medicine, an approach that focuses on personalization and collaboration. Learn more now.
A new immunotherapy drug combination has been dubbed a significant advancement in kidney cancer treatment. The combination of ipilimumab and nivolumab can improve outcomes and quality of life. Learn more.
Hans Hammers, M.D., Ph.D. /
James Brugarolas, M.D., Ph.D.